Adma Biologics (ADMA) Depreciation & Amortization (CF) (2011 - 2026)

Adma Biologics (ADMA) has 13 years of Depreciation & Amortization (CF) data on file, last reported at $2.0 million in Q4 2025.

• Quarterly Depreciation & Amortization (CF) rose 5.25% year-over-year to $2.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.1 million (up 0.63% YoY) and the FY2025 annual result came in at $8.1 million, up 0.63% from the prior year.
• Depreciation & Amortization (CF) advanced to $2.0 million in Q4 2025, from $2.0 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.1 million in Q1 2024 to a low of $1.2 million in Q1 2021.
• A 5-year average of $1.9 million and a median of $2.0 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2021 — Depreciation & Amortization (CF) soared 55.88% — and 2024, when it slipped 7.82%.
• Tracing ADMA's Depreciation & Amortization (CF) over 5 years: stood at $1.5 million in 2021, then advanced by 27.55% to $1.9 million in 2022, then grew by 8.91% to $2.1 million in 2023, then slipped by 7.82% to $1.9 million in 2024, then increased by 5.25% to $2.0 million in 2025.
• The last three Depreciation & Amortization (CF) figures came in at $2.0 million (Q4 2025), $2.0 million (Q3 2025), and $2.1 million (Q2 2025), per Business Quant data.